Antabio’s Novel Metallo β-Lactamase Inhibitor to be presented at the ASM Microbe Conference, June 20-24, San Francisco

Marc Lemonnier appointed at the Scientific Advisory Board of JPIAMR

ANTABIO Completes € 12.5M Series A

First publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor program

ANTABIO Announces Key Executive Appointments

ANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections

ANTABIO awarded up to $8.9M from CARB-X to accelerate the development of its new treatment for chronic infections in Cystic Fibrosis patients

Marc Lemonnier elected at the Board of the BEAM Alliance